Medico Remedies Ltd.
•Add ratio to table
ABOUT
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Company has delivered good profit growth of 38.3% CAGR over last 5 years
- Company has a healthy return on capital (ROCE) of 22.3%
- Latest quarter profit grew 38.4% YoY, showing strong momentum
- Stock looks reasonably valued - P/E of 22.1 is below its historical median
- Company comfortably covers its interest (11.0x coverage)
- Company generates healthy free cash flow
CONS
- Promoter holding has decreased over last 2 years: -12.0pp
- A large part of profit comes from other income (32.9% of PBT)
- Poor cash conversion - profits are not backed by operating cash flow (CFO/PAT 0.42x)
- Total debt has risen sharply - up 36.7% year on year
- Though reporting repeated profits, the company pays out little dividend (0.0%)
- Growth is decelerating - 3Y profit CAGR (21.9%) trails the 5Y trend (38.3%)
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1842.00 | 36.54 | 441957.50 | 0.87 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9326.00 | 84.64 | 247576.00 | 0.32 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4975.00 | 86.76 | 189233.01 | 0.76 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| ZYDUSLIFE | 1119.50 | 24.74 | 111670.55 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| CIPLA | 1365.00 | 32.72 | 110272.68 | 0.95 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| LAURUSLABS | 1970.35 | 97.37 | 106460.42 | 0.10 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| DRREDDY | 1161.00 | 30.07 | 96906.38 | 0.69 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| AUROPHARMA | 1675.45 | 25.97 | 96401.69 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| LUPIN | 2096.00 | 17.34 | 95842.92 | 0.86 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| MANKIND | 2277.00 | 46.04 | 94050.37 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| GLENMARK | 2416.90 | 37.94 | 68210.88 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| MEDICO | 36.73 | 22.06 | 304.80 | 0.00 | 2.52 | 38.35 | 69.40 | 81.44 | 23.28 | 4.75 |
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 31 | 42 | 30 | 41 | 31 | 39 | 39 | 41 | 38 | 53 | 59 | 57 | 69 | |
| 29 | 39 | 27 | 37 | 28 | 37 | 36 | 35 | 35 | 50 | 54 | 50 | 67 | |
| Operating Profit | 2 | 3 | 3 | 5 | 3 | 2 | 3 | 7 | 3 | 3 | 4 | 7 | 2 |
| OPM % | 7.82% | 7.27% | 9.17% | 11.23% | 9.12% | 6.12% | 7.88% | 16.13% | 7.37% | 5.17% | 7.38% | 12.59% | 3.13% |
| 0 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 2 | 1 | 3 | 1 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before Tax | 2 | 3 | 2 | 4 | 2 | 2 | 4 | 6 | 2 | 3 | 4 | 8 | 3 |
| Tax % | 29.79% | 22.93% | 30.10% | 27.06% | 27.52% | 27.23% | 25.14% | 23.86% | 25.51% | 26.22% | 25.07% | 29.57% | 24.62% |
| Net Profit | 1 | 2 | 1 | 3 | 2 | 2 | 3 | 4 | 2 | 3 | 3 | 6 | 3 |
| 0.16 | 0.29 | 0.17 | 0.37 | 0.19 | 0.19 | 0.32 | 0.52 | 0.22 | 0.31 | 0.35 | 0.71 | 0.30 |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 54 | 61 | 98 | 89 | 122 | 121 | 140 | 145 | 151 | 206 | 238 | |
| 50 | 58 | 95 | 86 | 117 | 114 | 131 | 132 | 137 | 189 | 221 | |
| Operating Profit | 4 | 3 | 3 | 3 | 5 | 7 | 9 | 13 | 14 | 17 | 16 |
| OPM % | 7.37% | 5.70% | 2.83% | 3.21% | 4.28% | 6.06% | 6.75% | 8.91% | 9.55% | 8.25% | 6.89% |
| 0 | 1 | 2 | 2 | 1 | 2 | 4 | 2 | 3 | 6 | 6 | |
| Interest | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 |
| Depreciation | 1 | 1 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 3 |
| Profit before Tax | 2 | 2 | 2 | 2 | 4 | 6 | 10 | 11 | 14 | 18 | 19 |
| Tax % | 3.56% | 34.84% | 27.81% | 26.40% | 30.00% | 25.78% | 28.29% | 26.86% | 25.26% | 27.38% | 27.17% |
| Net Profit | 2 | 1 | 2 | 2 | 3 | 5 | 7 | 8 | 10 | 13 | 14 |
| EPS | 0.00 | 0.00 | 0.00 | 3.93 | 6.25 | 2.90 | 0.87 | 1.00 | 1.22 | 1.58 | — |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- 12%
- 5 Years:
- 11%
- 3 Years:
- 14%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- 28%
- 5 Years:
- 38%
- 3 Years:
- 22%
STOCK PRICE CAGR
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- -21%
- 1 Year:
- -6%
RETURN ON EQUITY
- 10 Years:
- 12%
- 5 Years:
- 17%
- 3 Years:
- 18%
- Last Year:
- 19%
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3 | 4 | 4 | 4 | 4 | 17 | 17 | 17 | 17 | 17 |
| 13 | 23 | 24 | 26 | 28 | 20 | 27 | 36 | 46 | 59 | |
| 19 | 12 | 13 | 12 | 13 | 12 | 10 | 8 | 14 | 19 | |
| Trade Payables | 12 | 18 | 33 | 26 | 25 | 27 | 31 | 32 | 35 | 49 |
| 1 | 3 | 3 | 7 | 5 | 3 | 5 | 7 | 8 | 9 | |
| Total Liabilities | 48 | 59 | 76 | 75 | 76 | 79 | 89 | 98 | 120 | 153 |
| 7 | 7 | 12 | 13 | 15 | 18 | 22 | 21 | 21 | 20 | |
| Capital Work in Progress | 3 | 4 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 3 |
| 0 | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 2 | 2 | |
| 10 | 15 | 16 | 18 | 15 | 18 | 20 | 16 | 27 | 30 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 50 | 57 | 82 | |
| Cash & Bank | 1 | 1 | 1 | 1 | 3 | 2 | 1 | 0 | 1 | 2 |
| 28 | 32 | 46 | 41 | 42 | 40 | 45 | 9 | 11 | 14 | |
| Total Assets | 48 | 59 | 76 | 75 | 76 | 79 | 89 | 98 | 120 | 153 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| -2 | 6 | 6 | 2 | -10 | 8 | 11 | 2 | 5 | 6 | |
| Cash from Investing | -3 | -5 | -4 | -3 | -17 | -2 | -7 | -3 | -3 | -5 |
| Cash from Financing | 6 | -1 | -1 | 3 | 18 | -6 | -2 | -0 | -1 | -1 |
| -0 | -0 | -0 | 0 | -10 | -2 | -0 | -1 | 1 | 1 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-08-29 - Medico Remedies Limited has informed the Exchange about Book Closure Dates.
2026-08-29 - Medico Remedies Limited has informed the Exchange regarding Notice of undefined to be held on September 22, 2026
2026-08-13 - Medico Remedies Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-08-05 - Medico Remedies Limited has informed the Exchange about Bagging/Receiving of orders/contracts
2026-08-03 - Significant movement in price has been observed in Medico Remedies Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.
2026-06-30 - Medico Remedies Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
2026-06-29 - Medico Remedies Limited has informed the Exchange about Credit Rating
2026-06-03 - Medico Remedies Limited has informed the Exchange about Action(s) taken or orders passed
2026-06-01 - Harshit Mehta has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011
News
Recent coverage and analyst commentary for MEDICO
Loading news…
AI Stock Analyst
Medico Remedies Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account